Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922308 · ClinicalTrials.gov registry record · Phase 2
Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT03922308 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 28 participants.
The verdict
NCT03922308, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) treatment of acquired thrombotic thrombocytopenic purpura (aTTP) participants.
Interventions
- OTHER Placebo
- OTHER Standard of Care
- DRUG SHP655
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-10-09 |
| Est. Completion | 2021-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03922308
The ClinicalTrials.gov registry entry for NCT03922308 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03922308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03922308 about?
NCT03922308 is a clinical study titled "Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)". The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) treatment of acquired thrombotic thrombocytopenic purpura (aTTP) participants.
What is the current status of trial NCT03922308?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2019-10-09. Estimated completion is 2021-08-05.
What interventions are being tested in trial NCT03922308?
The interventions under investigation include: Placebo (OTHER), Standard of Care (OTHER), SHP655 (DRUG).
Who is sponsoring clinical trial NCT03922308?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.